EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Microbiome–Genome Crosstalk in Colorectal Cancer: Colibactin Signatures and Fusobacterium nucleatum in Epidemiology, Driver Selection, and Translation

Sungwon Jung iD

International Journal of Molecular Sciences · 23.02.2026 · 27 (4) · 2068

DOI: 10.3390/ijms27042068 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 23.02.2026. Verfasst von Sungwon Jung. Beteiligte Einrichtung: Department of Genome Medicine and Science, Gachon University College of Medicine, Incheon 21565, Republic of Korea. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Fusobacterium nucleatum, Polyketides, Peptides. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Korea.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Colibactin, a genotoxin produced by pks+ E. coli, imprints highly specific mutational signatures SBS88 and ID18 in colorectal cancer (CRC) and even in normal colonic crypts. Population-scale analyses show these signatures are enriched in early-onset CRC, vary geographically, and are imprinted early during tumor evolution, where probabilistic attribution indicates that colibactin contributes to a measurable fraction of APC driver mutations in colibactin-positive cancers. Beyond colibactin, Fusobacterium nucleatum exerts clade-specific effects on tumor ecology and therapy response, with data supporting both chemoresistance and sensitization to anti-PD-1 in microsatellite stable (MSS) CRC. This article covers mechanistic, genomic, and molecular epidemiology evidence, outlines analytic standards for signature detection (whole-genome sequencing (WGS)/whole-exome sequencing (WES), single-sample fitting, and limits at low mutation counts), and charts translational paths spanning noninvasive screening (stool metagenomics + mutational signatures in tissue/circulating tumor DNA (ctDNA)), risk stratification, and microbial-targeted interventions (antibiotics, phages, ClbP inhibitors). Framing microbiome–genome crosstalk as a tractable axis enables testable clinical hypotheses for precision oncology.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsFusobacterium nucleatumPolyketidesPeptidesMicrobiotaHumansMutation

Stichwörter der Autor:innen

Fusobacterium nucleatumcolibactincolorectal cancermicrobiome–genome crosstalkmolecular epidemiologymutational signaturesprecision oncology

Substanzen

colibactinPolyketidesPeptides

Autor:innen und Institutionen

  • Department of Genome Medicine and Science, Gachon University College of Medicine, Incheon 21565, Republic of Korea.
  • Gachon Institute of Genome Medicine and Science, Gachon University Gil Medical Center, Incheon 21565, Republic of Korea.

ORCID-Profile: Sungwon Jung

Förderung

  • National Research Foundation of Korea

Zitieren

APA

Jung, S. (2026). Microbiome–Genome Crosstalk in Colorectal Cancer: Colibactin Signatures and Fusobacterium nucleatum in Epidemiology, Driver Selection, and Translation. International Journal of Molecular Sciences, 27(4), 2068. https://doi.org/10.3390/ijms27042068

Vancouver

Jung S. Microbiome–Genome Crosstalk in Colorectal Cancer: Colibactin Signatures and Fusobacterium nucleatum in Epidemiology, Driver Selection, and Translation. International Journal of Molecular Sciences. 2026;27(4):2068. doi:10.3390/ijms27042068

BibTeX
@article{Jung2026,
  author = {Jung, Sungwon},
  title = {Microbiome–Genome Crosstalk in Colorectal Cancer: Colibactin Signatures and Fusobacterium nucleatum in Epidemiology, Driver Selection, and Translation},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  volume = {27},
  number = {4},
  pages = {2068},
  doi = {10.3390/ijms27042068}
}
Kostenlos starten →